{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:26:57Z","timestamp":1777904817755,"version":"3.51.4"},"reference-count":17,"publisher":"Society of Nuclear Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,1,29]]},"published-print":{"date-parts":[[2026,5]]},"DOI":"10.2967\/jnumed.125.271296","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:20:14Z","timestamp":1772727614000},"page":"739-743","source":"Crossref","is-referenced-by-count":0,"title":["Prostate-Specific Membrane Antigen Radioligand Therapy in Patients with Aggressive-Variant Prostate Cancer"],"prefix":"10.2967","volume":"67","author":[{"given":"Moein","family":"Moradpour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abuzar","family":"Moradi Tuchayi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surekha","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabin George","family":"Pop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devaki Shilpa","family":"Surasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishan","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"de Kouchkovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"Flavell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1602","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"2026050105301236000_67.5.739.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"2026050105301236000_67.5.739.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.03.028"},{"key":"2026050105301236000_67.5.739.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00524-7"},{"key":"2026050105301236000_67.5.739.4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3309"},{"key":"2026050105301236000_67.5.739.5","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.3390\/cancers12123792","article-title":"Neuroendocrine and aggressive-variant prostate cancer","volume":"12","author":"Spetsieris","year":"2020","journal-title":"Cancers (Basel)."},{"key":"2026050105301236000_67.5.739.6","doi-asserted-by":"crossref","first-page":"14948","DOI":"10.3390\/ijms232314948","article-title":"Salvage chemotherapy with cisplatin, ifosfamide, and paclitaxel in aggressive variant of metastatic castration-resistant prostate cancer","volume":"23","author":"von Amsberg","year":"2022","journal-title":"Int J Mol Sci."},{"key":"2026050105301236000_67.5.739.7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.clgc.2023.12.016","article-title":"Combined cabazitaxel and carboplatin treatment of metastatic castration resistant prostate cancer patients, with innate or acquired resistance to cabazitaxel monotherapy","volume":"22","author":"van der Zande","year":"2024","journal-title":"Clin Genitourin Cancer."},{"key":"2026050105301236000_67.5.739.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3791"},{"key":"2026050105301236000_67.5.739.9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/ijms26020679","article-title":"Clinical and genomic features of androgen indifferent prostate cancer","volume":"26","author":"Masur","year":"2025","journal-title":"Int J Mol Sci."},{"key":"2026050105301236000_67.5.739.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00332-5"},{"key":"2026050105301236000_67.5.739.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026050105301236000_67.5.739.12","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet."},{"key":"2026050105301236000_67.5.739.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2026050105301236000_67.5.739.14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.2018.36.6_suppl.193","article-title":"Influence of aggressive-variant prostate cancer (AVPC) features on outcome of metastatic hormone-sensitive prostate cancer (mHSPC) treated by chemohormonal therapy (CHT) [abstract]","volume":"36","author":"Koczka","year":"2018","journal-title":"J Clin Oncol."},{"key":"2026050105301236000_67.5.739.15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","article-title":"Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer","volume":"4","author":"Bakht","year":"2023","journal-title":"Nat Cancer."},{"key":"2026050105301236000_67.5.739.16","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.12998\/wjcc.v11.i26.6213","article-title":"Aggressive variant prostate cancer: a case report and literature review","volume":"11","author":"Weng","year":"2023","journal-title":"World J Clin Cases."},{"key":"2026050105301236000_67.5.739.17","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02255-y"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.271296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:31:12Z","timestamp":1777638672000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.271296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":17,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,1]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.2967\/jnumed.125.271296"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.271296","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]}}}